Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

PTC Therapeutics, Inc. (PTCT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.82-1.25 (-3.12%)
At close: 04:00PM EST
38.82 0.00 (0.00%)
After hours: 05:21PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close40.07
Open39.50
Bid38.94 x 900
Ask46.00 x 1000
Day's Range38.58 - 40.45
52 Week Range34.85 - 66.01
Volume690,630
Avg. Volume686,050
Market Cap2.744B
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-6.50
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est52.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PTCT

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PTC Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • PR Newswire

    PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the eighth annual STRIVE™ awards program for Duchenne muscular dystrophy (Duchenne). Through this program, PTC provides grants to patient advocacy organizations who are committed to developing initiatives that address the unmet needs of the Duchenne community. Organizations may apply for a grant to fund their projects focused on one of two categories: Innovation or Transition to Adulthood.

  • PR Newswire

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 7, 2022, the company approved non-statutory stock options to purchase an aggregate of 18,255 shares of its common stock and 10,675 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 26 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.

  • PR Newswire

    PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program

    PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company's 2022 Talent Pipeline Program, a one-year, global initiative designed to provide recent college graduates with high-quality, real-world opportunities at work. Throughout this immersive program, participants receive benefits such as mentorship, job coaching, career counseling and leadership development training.

Advertisement
Advertisement